Bogdana Kovalchuk, Anna S Berghoff, Matthia A Karreman, Katharina Frey, Manuel Piechutta, Manuel Fischer, Julia Grosch, Sabine Heiland, Michael O Breckwoldt, Frank Hilberg, Wolfgang Wick, Frank Winkler
Brain metastases (BM) are an ever-increasing challenge in oncology, threatening quality of life and survival of many cancer patients. The majority of BM originate from lung adenocarcinoma, and stage III patients have a risk of 40-50% to develop BM in the first years of disease onset. As therapeutic options are limited, prevention of their occurrence is an attractive concept. Here we investigated whether Nintedanib (BIBF 1120), a tyrosine kinase inhibitor (TKI) targeting the VEGF pathway approved for lung adenocarcinoma, and the dual anti-VEGF-A/Ang2 nanobody BI836880 have the potential to prevent BM formation...
September 12, 2020: Clinical & Experimental Metastasis